Novel Molecular Strategies and Targets for Opioid Drug Discovery for the Treatment of Chronic Pain
Open Access
- 29 March 2017
- journal article
- review article
- Vol. 90 (1), 97-110
Abstract
Opioid drugs like morphine and fentanyl are the gold standard for treating moderate to severe acute and chronic pain. However, opioid drug use can be limited by serious side effects, including constipation, tolerance, respiratory suppression, and addiction. For more than 100 years, we have tried to develop opioids that decrease or eliminate these liabilities, with little success. Recent advances in understanding opioid receptor signal transduction have suggested new possibilities to activate the opioid receptors to cause analgesia, while reducing or eliminating unwanted side effects. These new approaches include designing functionally selective ligands, which activate desired signaling cascades while avoiding signaling cascades that are thought to provoke side effects. It may also be possible to directly modulate downstream signaling through the use of selective activators and inhibitors. Separate from downstream signal transduction, it has also been found that when the opioid system is stimulated, various negative feedback systems are upregulated to compensate, which can drive side effects. This has led to the development of multi-functional molecules that simultaneously activate the opioid receptor while blocking various negative feedback receptor systems including cholecystokinin and neurokinin-1. Other novel approaches include targeting heterodimers of the opioid and other receptor systems which may drive side effects, and making endogenous opioid peptides druggable, which may also reduce opioid mediated side effects. Taken together, these advances in our molecular understanding provide a path forward to break the barrier in producing an opioid with reduced or eliminated side effects, especially addiction, which may provide relief for millions of patients.Keywords
This publication has 105 references indexed in Scilit:
- μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: From a symposium on new concepts in mu-opioid pharmacologyDrug and Alcohol Dependence, 2011
- Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic painBrain Research, 2011
- The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeuticsNeuropharmacology, 2011
- Design and synthesis of trivalent ligands targeting opioid, cholecystokinin, and melanocortin receptors for the treatment of painBioorganic & Medicinal Chemistry Letters, 2010
- Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activityNeuroscience, 2010
- Kinase cascades and ligand-directed signaling at the kappa opioid receptorPsychopharmacology, 2010
- Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1βNeuroscience, 2010
- Evidence for a role of heat shock protein-90 in toll like receptor 4 mediated pain enhancement in ratsNeuroscience, 2009
- Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesiaEuropean Journal of Pharmacology, 2008
- Proinflammatory cytokines oppose opioid-induced acute and chronic analgesiaBrain, Behavior, and Immunity, 2008